Kai Rejeski

@KRejeski

Research Group Leader @LMU | Visiting Investigator @MSKCC | Interested in novel biomarkers and modelling CAR-T toxicity and response | 🇩🇪🇺🇸

Joined August 2019

347Following

1KFollowers

Pinned

Kai Rejeski@KRejeski · Jul 8, 2024

🚨 hot off the press 🚨 A (perhaps) underestimated aspect of CAR T-cell therapy: non-relapse mortality. Check out our new meta-analysis on this clinically relevant topic - out today in @NatureMedicine ! nature.com/articles/s4159… Let’s take a deeper dive! Start 🧵

KRejeski's tweet card. Nature Medicine - In a systematic review and meta-analysis of nonrelapse mortality (NRM) following CAR T cell treatment in 7,604 patients with lymphoma and myeloma, almost half of cases were...

158

50.0K

Pinned

Kai Rejeski Retweeted

MSK Department of Medicine@MSK_DeptOfMed · Apr 24

Congrats to @KRejeski, @RShouval, and their team on developing a new grading system to evaluate patterns of thrombocytopenia in patients treated with commercial CD19 CAR-T therapy for B-cell non-Hodgkin #lymphoma. @BloodJournal Read the study: bit.ly/42FHRgd

2.0K

Kai Rejeski Retweeted

Robert Z. Orlowski@Myeloma_Doc · Jul 22

#Myeloma Paper of the Day: Viewpoint piece makes evidence-based arguments for use of primary prophylaxis as a safer and simpler approach compared to preemptive IgG-guided immunoglobulin replacement therapy in pts getting bispecific antibodies: pubmed.ncbi.nlm.nih.gov/40690761/. #mmsm

2.0K

Kai Rejeski Retweeted

Nature Medicine@NatureMedicine · Jul 21

Our latest Review summarizes the current knowledge on mortality-defining toxicities of #CARTcell therapies, beyond CRS and ICANS. @KRejeski & colleagues discuss underlying mechanisms of rare and long-term toxicities and how these affect timing and management, and outline key…

5.0K

Kai Rejeski@KRejeski · Jun 26

Beautiful paper by my good friend @pkarschnia, amazing to see all your academic progress in the last decade! Highly recommended reading out in @NatRevNeurol on all things CAR-T neurotoxicity - from ICANS to TIAN and MNTs👇

NNat Rev Neurology@NatRevNeurol · Jun 25

New online! Neurological complications of CAR T cell therapy for cancers bit.ly/4eqkbCe

3.0K

Kai Rejeski@KRejeski · Jun 24

Thanks for shining a light on our recent paper on nonrelapse mortality with bispecifics with this informative commentary - enjoyed reading it @RahulBanerjeeMD and @samyamshon !

RRahul Banerjee, MD, FACP@RahulBanerjeeMD · Jun 24

Pleasure co-writing @MolTherapy commentary with @samyamshon on excellent meta-analysis of bsAb NRM in #lymsm #MMsm. 1️⃣ Many mechanisms: largely infectious, not CRS 2️⃣ Yes, early C19 years contributed to deaths - but does not exculpate this class 3️⃣ Better IVIG guidance needed!

1.0K

Kai Rejeski@KRejeski · Jun 18

What an absolute tour-de-force just published in Cancer Cell by @GreenLymphoLab and colleagues ! Using single-nucleus multiome profiling of 232 (!) lymphoma samples, they uncover distinct tumor microenvironmental features, relevant for response to CART19 ☝️

MMichael Green, PhD@GreenLymphoLab · Jun 18

Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by @dgermain21 at #18icml @icmlugano, now available online in Cancer Cell. #lmsm @washumedicine @MDAndersonNews. cell.com/cancer-cell/fu…

563

Kai Rejeski@KRejeski · Jun 15

Great work by @YiLinMDPhD and team from @MayoCancerCare on potential predictors of IEC CNP and Parkinsonism presented at this years #EHA25

YYi Lin@YiLinMDPhD · Jun 15

Great job @Kennethjclim presenting @MayoCancerCare risk factor of IEC-nerve palsy & Parkinsonism #EHA25 #mmsm Hopefully we will learn soon from CARTITUDE trials & RWE across centers whether additional early mitigating strategies could reduce the risk further @IMFmyeloma

867

Kai Rejeski@KRejeski · Jun 13

Whirlwind day at #EHA25 presenting first on eligibility + longterm safety of CAR-T in 2L LBCL and then receiving this years EHA Publication Award for our ICAHT work in the Presidential Session 🙌 Grateful to share these moments with friends, collaborators and fantastic mentors!

KRejeski's tweet image. Whirlwind day at #EHA25 presenting first on eligibility + longterm safety of CAR-T in 2L LBCL and then receiving this years EHA Publication Award for our ICAHT work in the Presidential Session 🙌

Grateful to share these moments with friends, collaborators and fantastic mentors!

3.0K

Kai Rejeski Retweeted

Suzanne Lentzsch, MD, PhD@SLentzsch · Jun 10

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

113

16.0K

Kai Rejeski Retweeted

Roni Shouval@RShouval · Jun 4

📢 New Review Out in @Haematologica! Together with Ofrat Beyar Katz and @KRejeski, we discuss hematologic toxicities of CAR-T therapy—definitions, mechanisms, and clinical impact. Read the full review 👉 haematologica.org/article/view/1… #CAR_T #Hematology #Toxicity

2.0K

Kai Rejeski Retweeted

VJHemOnc@VJHemOnc · May 20

#iwCART25 | @KRejeski discusses non-relapse mortality in patients receiving CAR T-cells and bispecifics, highlighting the main drivers of NRM: 🎥 ow.ly/p5TA50VRCAW #CARTCell #ImmunoOnc #HemOnc #LYMsm #MMSM #Myeloma #Lymphoma #MultipleMyeloma

730

Kai Rejeski Retweeted

Heidelberg Myeloma@HDMyeloma · Apr 27

Second day of the 10th Heidelberg Myeloma Workshop How to further improve on CAR-Ts? @KRejeski @szusmani @H_Einsele @JHillengass Jens Lohr #mmsm

1.0K

Kai Rejeski Retweeted

Clinical Cancer Research@CCR_AACR · Apr 26

A must read if you are heading to the #AACR25 session on CAR-T Cells in Hematological Malignancies: Innovations and Pitfalls from @KRejeski @MSKCancerCenter. brnw.ch/21wSePV

3.0K